{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:18:44Z","timestamp":1787631524875,"version":"build-2736575974"},"reference-count":73,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>The ability to undergo neoangiogenesis is a common feature with all cancers. Signaling related to vascular endothelial growth factors (VEGF) and their receptors (VEGFR) plays a key role in the process of tumor neoangiogenesis. A close relationship has been demonstrated between excessive VEGF levels and the induction of immunosuppression in the tumor microenvironment. The use of drugs blocking the VEGF function, apart from the anticancer effect, also result in adverse effects, in particular related to the circulatory system and kidneys. Cardiac toxicity associated with the use of such therapy manifests itself mainly in the form of hypertension, thromboembolic episodes and ischemic heart disease. In the case of renal complications, the most common symptoms include renal arterial hypertension, proteinuria and microangiopathy. Although these complications are reversible in 60\u201380% of cases after cessation of VSP (VEGF pathway inhibitor) therapy, in some cases they can lead to irreversible changes in renal function, whereas cardiac complications may be fatal. Also, the use of PD-1\/PD-L1 inhibitors may result in kidney and heart damage. In the case of cardiac complications, the most common symptoms include myocarditis, pericarditis, arrhythmia, acute coronary syndrome and vasculitis, while kidney damage most often manifests as acute kidney injury (AKI), nephrotic syndrome, pyuria or hematuria. The decision whether to resume treatment after the occurrence of cardiovascular and renal complications remains a problem.<\/jats:p>","DOI":"10.3390\/genes15020177","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T08:11:27Z","timestamp":1706515887000},"page":"177","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor\/Programmed Cell Death Protein 1 Ligand Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Paulina","family":"Stachyra-Strawa","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lublin, Chod\u017aki 7, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Szatkowska-Sieczek","sequence":"additional","affiliation":[{"name":"Clinical Department of Cardiology, 4th Military Hospital, Rudolfa Weigla 5, 50-981 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Cisek","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lublin, Chod\u017aki 7, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Go\u0142\u0119biowski","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lublin, Chod\u017aki 7, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmi\u0142a","family":"Grzybowska-Szatkowska","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lublin, Chod\u017aki 7, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9440(10)64920-6","article-title":"Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors","volume":"160","author":"Morikawa","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0002-9440(10)63540-7","article-title":"Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors","volume":"163","author":"Baluk","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Geindreau, M., Ghiringhelli, F., and Bruchard, M. (2021). Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094871"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF\/VEGFR Pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Chebotareva, N., Grechukhina, K., Mcdonnell, V., Zhukova, L., and Krasnova, T. (2022). Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs. Biomed. Rep., 16.","DOI":"10.3892\/br.2022.1529"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11886-021-01440-3","article-title":"Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies","volume":"23","author":"Rothberg","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1634\/theoncologist.2018-0764","article-title":"Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review","volume":"24","author":"Sise","year":"2019","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.6004\/jnccn.2011.0038","article-title":"A review of VEGF\/VEGFR-targeted therapeutics for recurrent glioblastoma","volume":"9","author":"Reardon","year":"2011","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bolcaen, J., Nair, S., Driver, C.H.S., Boshomane, T.M.G., Ebenhan, T., and Vandevoorde, C. (2021). Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070626"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1247\/csf.26.25","article-title":"Structure and function of VEGF\/VEGF-receptor system involved in angiogenesis","volume":"26","author":"Shibuya","year":"2001","journal-title":"Cell Struct. Funct."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: Current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3892\/or.2021.8109","article-title":"The role of immunotherapy and molecular-targeted therapy in the treatment of melanoma (Review)","volume":"46","author":"Ciesielka","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers7030860","article-title":"Targeting RTK signaling pathways in cancer","volume":"7","author":"Regad","year":"2015","journal-title":"Cancers"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Figueras, A., Arbos, M.A., Quiles, M.T., Vi\u00f1als, F., Germ\u00e0, J.R., and Capell\u00e0, G. (2013). The impact of KRAS mutations on VEGF-A production and tumour vascular network. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-125"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.molcel.2018.08.005","article-title":"Structural basis for regulation of phosphoinositide kinases and their involvement in human disease","volume":"71","author":"Burke","year":"2018","journal-title":"Mol. Cell."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends. Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of program-med death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic effects of angiogenesis inhibitors","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: Understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardio- vascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis","volume":"53","author":"Ethier","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","unstructured":"Bernard, G. (2000). Mayo Clinic Heart Book, William Morrow & Co."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00897","DOI":"10.1002\/prp2.897","article-title":"Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_31","first-page":"49","article-title":"Cardiovascular complications of antiangiogenic therapy in ovarian cancer patients","volume":"13","author":"Wilk","year":"2017","journal-title":"Oncol. Clin. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/bmj.39276.636354.AE","article-title":"Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: Systematic review","volume":"6","author":"Pewsner","year":"2007","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100338","DOI":"10.1016\/j.esmoop.2021.100338","article-title":"Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: A real-life study and proposed algorithm for proactive management","volume":"7","author":"Vallerio","year":"2022","journal-title":"ESMO Open"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.bjc.6604709","article-title":"Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Billemont","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_35","unstructured":"(2023, July 09). National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ctrv.2017.07.006","article-title":"Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies","volume":"59","author":"Santoni","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus Sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Chen, X.L., Lei, Y.H., Liu, C.F., Yang, Q.F., Zuo, P.Y., Liu, C.Y., Chen, C.Z., and Liu, Y.W. (2013). Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: A meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066721"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Faruque, L.I., Lin, M., Battistella, M., Wiebe, N., Reiman, T., Hemmelgarn, B., Thomas, C., and Tonelli, M. (2014). Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101145"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e31828b73ff","article-title":"A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel","volume":"61","author":"Vermorken","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zang, J., Wu, S., Tang, L., Xu, X., Bai, J., Ding, C., Chang, Y., Yue, L., Kang, E., and He, J. (2012). Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: A systematic review and meta-analysis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030353"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2020.08.033","article-title":"Cardiotoxic mechanisms of cancer immunotherapy\u2014A systematic review","volume":"323","author":"Lobenwein","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Van Wynsberghe, M., Flejeo, J., Sakhi, H., Ollero, M., Sahali, D., Izzedine, H., and Henique, C. (2021). Nephrotoxicity of Anti-Angiogenic Therapies. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040640"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF Inhibition, Hypertension, and Renal Toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ndt\/gfl711","article-title":"Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia","volume":"22","author":"Garovic","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bor\u00f3wka, M., \u0141\u0105cki-Zynzeling, S., Nicze, M., Kozak, S., and Chudek, J. (2022). Adverse Renal Effects of Anticancer Immunotherapy: A Review. Cancers, 14.","DOI":"10.20944\/preprints202207.0256.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.34067\/KID.0000852019","article-title":"Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020","volume":"1","author":"Gupta","year":"2020","journal-title":"Kidney360"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"206","DOI":"10.20892\/j.issn.2095-3941.2015.0070","article-title":"Relationship of vegf\/vegfr with immune and cancer cells: Staggering or forward?","volume":"13","author":"Li","year":"2016","journal-title":"Cancer Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ijc.26094","article-title":"Vegf directly suppresses activation of t cells from ovarian cancer patients and healthy individuals via vegf receptor type 2","volume":"130","author":"Ziogas","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11523-022-00866-1","article-title":"Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma","volume":"17","author":"Markham","year":"2022","journal-title":"Target Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: A systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11923","DOI":"10.1038\/s41598-023-39076-8","article-title":"Developing a dual VEGF\/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy","volume":"13","author":"Tzuri","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Xiong, C., Mao, Y., Wu, T., Kang, N., Zhao, M., Di, R., Li, X., Ji, X., and Liu, Y. (2018). Optimized expression and characterization of a novel fully human bispecific single-chain diabody targeting vascular endothelial growth factor165 and programmed death-1 in Pichia pastoris and evaluation of antitumor activity in vivo. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102900"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2017.09.017","article-title":"Genetic predisposition to bevacizumab-induced hypertension","volume":"147","author":"Frey","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41416-021-01557-w","article-title":"Bevacizumab-induced hypertension and proteinuria: A genome-wide study of more than 1000 patients","volume":"126","author":"Quintanilha","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_67","first-page":"685","article-title":"Genetic markers of bevacizumab-induced hypertension","volume":"17","author":"Lambrechts","year":"2014","journal-title":"Angiogenesis"},{"key":"ref_68","first-page":"503","article-title":"Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) predict sunitinib-induced hypertension","volume":"92","author":"Eechoute","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/tpj.2015.100","article-title":"Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma","volume":"17","author":"Diekstra","year":"2017","journal-title":"Pharmacogenom. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"20089","DOI":"10.1038\/srep20089","article-title":"The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma","volume":"6","author":"Qin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_71","unstructured":"(2023, August 20). What Are Genome-Wide Association Studies (GWAS)? EMBL-EBI Train Online. Available online: https:\/\/www.ebi.ac.uk\/training-\u03b2\/online\/courses\/gwas-catalogue-exploring-snp-trait-associations\/what-is-gwas-catalog\/what-are-genome-wide-association-studies-gwas\/."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","article-title":"Germline variants associated with toxicity to immune checkpoint blockade","volume":"28","author":"Groha","year":"2022","journal-title":"Nat. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2217\/pgs-2022-0113","article-title":"Association between genetic variants and the risk of nivolumab-induced immune-related adverse events","volume":"23","author":"Udagawa","year":"2022","journal-title":"Pharmacogenomics"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/2\/177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:50:44Z","timestamp":1760104244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/2\/177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["genes15020177"],"URL":"https:\/\/doi.org\/10.3390\/genes15020177","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]}}}